ABOUT US

Created to develop and commercialise the use of therapeutics and diagnostics, Nexpep works in celiac disease.

Celiac disease is an immune disease of the small intestine caused by exposure to dietary gluten in wheat, rye, barley and oats.

Currently, the only treatment is a strict gluten-free diet.

Five million Europeans and North Americans are likely to have celiac disease.

Nexpep is developing novel diagnostics, preventatives, and a non-dietary therapeutic ‘vaccine’ product for celiac disease. Phase I clinical trials are due to begin in 2008.

With a second round capital raising underway, Nexpep continues to meet its scientific and commercial milestones.

Interested in partnering with medical research institutes and investors, Nexpep invites you to contact us for more information.